Publication Name	World Journal of Gastroenterology
Manuscript ID	5674
Country	Spain

Received	2013-09-23 10:00
Peer-Review Started	2013-09-24 09:46
To Make the First Decision	2013-12-04 09:21
Return for Revision	2013-12-05 11:14
Revised	2013-12-19 19:10
Second Decision	2014-04-16 11:06
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-16 12:23
Articles in Press	2014-05-23 10:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-21 13:59
Publish the Manuscript Online	2014-11-10 19:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Topic Highlights
Article Title	Immunogenetic biomarkers in inflammatory bowel diseases: Role of the IBD3 region
Manuscript Source	Invited Manuscript
All Author List	Manuel Muro, Ruth López-Hernández and Anna Mrowiec
Funding Agency and Grant Number	Funding Agency Grant Number Foundation Seneca 05748/PI/07 Foundation Seneca 04487/GERM/06 Fondo de Investigación Sanitaria (FIS) projects CIBERehd PI11/02644 Fondo de Investigación Sanitaria (FIS) projects CIBERehd PI11/02686 (in part) ISCII and Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS) CA11/00034 (to López-Hernández R)
Corresponding Author	Manuel Muro, PhD, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Immunology Service, University Hospital Virgen de la Arrixaca, Madrid-Cartagena s/n, El Palmar, 30120 Murcia, Spain. manuel.muro@carm.es
Key Words	IBD3; Tumor necrosis factor; MICA; HLA; Inflammatory bowel disease
Core Tip	This review gathers information about the importance of IBD3 genomic region in susceptibility to inflammatory bowel disease (IBD). The new and old immunogenetic biomarkers of the IBD3 region (human leukocyte antigen, MHC class Ⅰ chain-related molecule A, MHC class Ⅰ chain-related molecule B, and tumor necrosis factor-? and -?) and their role on IBD susceptibility are discussed in the light of recent publications. IBD3 gene polymorphisms and their clinical relevance for the treatment of the IBD patients are also discussed. Insights into the natural history of these complex diseases may allow in the future appropriate patient selection for early aggressive therapy aimed at modifying the course of the disease.
Publish Date	2014-11-10 19:10
Citation	Muro M, López-Hernández R, Mrowiec A. Immunogenetic biomarkers in inflammatory bowel diseases: Role of the IBD3 region. World J Gastroenterol 2014; 20(41): 15037-15048
URL	http://www.wjgnet.com/1007-9327/full/v20/i41/15037.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i41.15037

Full Article (PDF)	WJG-20-15037.pdf
Full Article (Word)	WJG-20-15037.doc
Manuscript File	5674-Review.doc
Answering Reviewers	5674-Answering reviewers.pdf
Copyright License Agreement	5674-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5674-Language certificate.pdf
Peer-review Report	5674-Peer reviewer(s).pdf
Scientific Editor Work List	5674-Scientific editor work list.doc